pharma · Kidney Dysfunction · Obesity
LianBio
Jian Li
Jian Li is a pharma organization headquartered in CN. Primary therapeutic focus areas include Kidney Dysfunction, Obesity, Fibrosis, Ebola Virus Disease, Bladder Cancer. NovaPharmaNews links 28 clinical program(s), 0 dru
Company details
- Status
- Public
- HQ
- CN
- Founded
- 2019
- Employees
- 47
- Programs
- 28
- Drugs
- 40
- Patents
- 0
Irinotecan liposome、5-Fluorouracil、Leucovorin
Phase 3 · small molecule · Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy
Irinotecan liposome、5-Fluorouracil、Leucovorin for Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy is a Phase 3 program (small_molecule) at Jian Li with 1 ClinicalTrials.gov record(s).
Internal code HR-IRI-APC
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Jian Li
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy
- Status
- completed
- Trials
- 1